Erasca, Inc. 10-Q Summary
Reporting period: Three months ended March 31, 2023; filed May 15, 2023. Erasca is a clinical-stage precision oncology company developing therapies for RAS/MAPK pathway-driven cancers. It has no approved products and has not generated product revenue.
Financial position and results
| Metric | Q1 2023 | Q1 2022 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $27.6 million | $27.4 million |
| In-process research and development expense | $0 | $2.0 million |
| General and administrative expense | $9.4 million | $7.1 million |
| Total operating expenses | $37.0 million | $36.5 million |
| Interest income | $3.9 million | $0.1 million |
| Net loss | $33.2 million | $36.5 million |
| Net loss per share | $0.22 | $0.31 |
| Net cash used in operating activities | $26.4 million | $25.8 million |
- Cash and cash equivalents were $272.8 million at March 31, 2023, compared with $284.2 million at December 31, 2022.
- Short-term marketable securities were $117.0 million, resulting in total cash, cash equivalents and short-term marketable securities of $389.7 million.
- Total assets were $467.5 million and total liabilities were $81.1 million at March 31, 2023.
- Accumulated deficit was $514.2 million; stockholders’ equity was $386.5 million.
- The company had no debt reported. Operating lease liabilities totaled $58.1 million, including $3.1 million current and $54.9 million noncurrent.
- Net cash used in operating activities was partially offset by $14.7 million of cash provided by investing activities, primarily reflecting marketable-security maturities. Financing activities provided $0.2 million from stock-option exercises.
Material changes versus the prior comparable period
- Net loss declined by $3.3 million, primarily because Q1 2022 included a $2.0 million Katmai development milestone recorded as in-process research and development expense and Q1 2023 benefited from substantially higher interest income.
- Research and development expense increased by $0.2 million. Higher facilities, depreciation, personnel and stock-based compensation costs were largely offset by lower clinical, preclinical, discovery and outsourced-service spending.
- General and administrative expense increased by $2.4 million, driven mainly by higher stock-based compensation, personnel costs, and facilities and office expenses.
- Cash used in operations increased by $0.6 million despite the lower net loss, while the cash balance declined by $11.5 million during the quarter.
- Shares outstanding increased modestly during the quarter, and weighted-average shares used in the loss-per-share calculation increased to 149.5 million from 119.5 million.
Guidance, outlook, risks and unusual items
- Management expects no product revenue for at least the next several years, if ever, unless a product candidate completes development and receives regulatory approval.
- Based on current operating plans, management believes its cash, cash equivalents and marketable securities will fund operations into the second half of 2025. The financial statements separately state that resources are expected to be sufficient for at least one year from issuance; both assessments are subject to execution, clinical, regulatory and financing risks.
- Management expects research and development and general and administrative expenses, and operating losses, to increase substantially as clinical trials and preclinical programs advance.
- Naporafenib is the lead program. The company planned to initiate a Phase 1b trial in the second half of 2023 and a pivotal Phase 3 trial in the first half of 2024 for selected RAS/MAPK-driven cancers.
- In December 2022, Erasca licensed naporafenib from Novartis for $20.0 million in cash and approximately $80.0 million of common stock. The agreement includes up to $80.0 million of regulatory milestones, up to $200.0 million of sales milestones, and low-single-digit royalties on net sales.
- Other licensing arrangements include potential development, regulatory and commercial milestone payments and royalties. No related milestones were accrued at March 31, 2023 because the contingencies were not considered probable or estimable.
- The company had an at-the-market facility allowing up to $200 million of common-stock sales, but reported no sales under the facility through March 31, 2023. Future equity or debt financing may be required and could dilute shareholders or impose restrictive terms.
- Available-for-sale securities had $542,000 of gross unrealized losses, which management attributed to market and interest-rate factors rather than credit risk.
- The company relies on third parties for manufacturing, clinical research, packaging, storage and distribution. Key risks include clinical-trial failure or delay, regulatory uncertainty, manufacturing and supply-chain disruption, intellectual-property challenges, inflation, financial-market instability and the inability to obtain additional capital.
- No material legal proceedings were outstanding, and management reported no material changes to previously disclosed risk factors or internal control over financial reporting.
Important facts for investors to verify
- Whether clinical and regulatory milestones for naporafenib, ERAS-007, ERAS-601 and other pipeline programs remain on schedule.
- The actual quarterly cash-burn rate and whether the projected funding runway into the second half of 2025 changes as trial costs and programs expand.
- Future equity issuance under the $200 million at-the-market facility or other financing, including potential dilution.
- The timing and probability of contingent milestone payments, royalty obligations and other commitments under licensing agreements.
- Clinical efficacy, safety, enrollment and manufacturing updates, particularly for planned pivotal or combination trials.
- The effect of long-term facility leases, with total remaining operating lease payments of $86.5 million as of March 31, 2023.